Patrik Brundin

Add links
From Wikipedia, the free encyclopedia
Patrik Brundin
Born
Patrik Brundin

(1961-12-26) December 26, 1961 (age 62)
Malmö, Sweden
NationalitySwedish
American
OccupationNeuroscientist
Known forResearch on Parkinson's disease (PD) and Huntington's disease

Patrik Brundin (born December 26, 1961, in Malmö, Sweden) is a neuroscientist known for his research on Parkinson's disease (PD) and Huntington's disease.[1][2][3] He is currently a Distinguished Scientist and serving as Therapeutic Area Leader for Movement Disorders at F. Hoffmann-La Roche, Pharmaceutical Research and Early Development (pRED).[4][5]

Brundin was educated at Lund University from 1980 to 1992, where he became a full professor in 2000. In 2012, he was appointed the Jay Van Andel Endowed Chair in Parkinson's Research at Van Andel Institute, Grand Rapids, Michigan.[6] Before moving to F. Hoffmann-La Roche in 2022, Brundin held multiple roles at the institute such as the Deputy Chief Scientific Officer, the Director of the Center for Neurodegenerative Science and the Parkinson's Disease Center.[7][8][9]

Early life and education[edit]

Already at age 12, Brundin became interested in studying and finding a cure for PD, a passion influenced by his father's, Bertil Brundin, diagnosis in 1974.[10][11][12] While born in Sweden, Brundin spent the majority of his early childhood in the UK, before the family's return to Sweden in 1975.[13][14]

In 1978, Brundin was granted a scholarship to United World College (UWC) of the Atlantic, an international boarding school in Wales, UK.[15][11] At age 17, he started his research with an Extended Essay on PD as part of the International Baccalaureate (IB) program.[10] Upon completion of his IB diploma in 1980, he entered medical school at Lund University in Sweden and embarked on an M.D.-Ph.D. program. He completed his Bachelor of Science in Medicine in 1983, a Ph.D. in 1988 under the supervision of Swedish neuroscientist Anders Björklund, and an M.D. in 1992.[16]

Career[edit]

In 1994, Brundin started his own independent research group at Lund University, Sweden, and he was promoted to full professor of neuroscience at the Faculty of Medicine in 2000.[17][18][19] His team moved to the Wallenberg Neuroscience Center at Lund University in 1996.[20]

In 2011, Brundin was awarded a European Research Council grant to study disease mechanisms in PD. In 2012, he moved to the USA and joined the Van Andel Institute, serving both as the Director of the Center for Neurodegenerative Science and the Head of the Laboratory for Translational Parkinson's Disease Research.[13][21] He later held positions as the Deputy Chief Scientific Officer and the Director of the Parkinson's Disease Center at the same institute until 2022.[9] During this period, he also chaired the scientific committee of the International Linked Clinical Trials initiative.[22] In 2022, he moved to F. Hoffmann-La Roche where he became a Distinguished Scientist where he has the role of Therapeutic Area Leader for Movement Disorders.[4]

Brundin is highly cited, with more than four hundred publications on PD and Huntington's Diseases.[22] He contributed to cell transplantation for PD, took part in initial successful clinical trials, and oversaw subsequent methodological refinements. His work expanded to include the molecular mechanisms of these diseases, co-authoring with Nobel laureate Aaron Ciechanover, a 2002 review on the potential role of impaired protein degradation in neurodegenerative disorders. He and collaborators identified the prion-like propagation of alpha-synuclein aggregates between neurons and developed corresponding animal models. This work contributed to the recognition of alpha-synuclein as a potential therapeutic target in PD.[23][24][25] In 2021, Brundin was listed on the Clarivate Highly Cited Researchers List.[22] Since 2022, at F. Hoffmann-La Roche, he has maintained his research focus on alpha-synuclein, participating in clinical trials studying this protein.

Brundin has also had several other scientific leadership roles. In 2011 he was a founding co-editor-in-chief of the Journal of Parkinson's Disease and he served in that role for over a decade.[4] Starting in 2012, he served for a decade as the inaugural chair of the International Linked Clinical Trials committee, which was instrumental in conducting the largest drug repurposing program in Parkinson's Disease (PD).[26] He has been a member of the World Parkinson Coalition Board of Directors and the MJ Fox Foundation Executive Scientific Advisory Board.[27][9] He has also chaired a study section at the National Institutes for Neurological Disease and Stroke (NINDS).[28] He is a scientific co-founder of the biotech companies Acousort AB and RYNE Biotechnology, the latter focused on induced pluripotent stem cell (iPSC)-based transplantation therapy for PD.[29]

Awards and recognition[edit]

  • 1999: Dr Eric K Fernström Foundation's Prize to Young Swedish Scientists[4]
  • 2001: Catedra Santiago Grisolía Chair Prize, Valencia, Spain[30]
  • 2001: Chair, Gordon Research Conference on CAG Triplet Repeat Disorders[31]
  • 2003: Medal of Honour from the Swedish Parkinson Association[30]
  • 2003: Bernard Sanberg Memorial Award[30]
  • 2004: Elected as member of Academia Europea[30]
  • 2011: Swedbank Scientific Award in the Memory of Amanda and Per Algot Mångberg[32]
  • 2018: Aligning Science Across Parkinson's Planning Advisory Council[33]
  • 2019: Fulton Lecture Award, World Federation of Neurology[34]
  • 2021: Clarivate Highly Cited Researchers List[22]
  • 2022: Honorary Award for Outstanding Contribution, Tom Isaacs Award[35]

References[edit]

Scholia has an author profile for Patrik Brundin.
  1. ^ "Möt en av världens främsta Parkinsonforskare". Sydsvenskan. March 19, 2011. Archived from the original on 2023-08-07. Retrieved 2023-08-07.
  2. ^ "Hopp om tidig medicin mot Parkinson". Dagens Nyheter. January 19, 2011. Archived from the original on August 7, 2023. Retrieved August 7, 2023 – via www.dn.se.
  3. ^ Sorenson, Aaron (2011). "Productivity and Impact of the Top 100 Cited Parkinson's Disease Investigators since 1985". Journal of Parkinson's Disease. Archived from the original on 25 October 2017. Retrieved 15 October 2018.
  4. ^ a b c d "Patrik Brundin Steps Down as JPD Co-Editor-in-Chief | Journal of Parkinson's Disease". Archived from the original on 2023-08-07. Retrieved 2023-08-07.
  5. ^ "Q&A with Dr. Patrik Brundin". Archived from the original on 2023-08-29. Retrieved 2023-08-29.
  6. ^ "Patrik Brundin, MD, PHD". Michael J. Fox Foundation for Parkinson's Research. Archived from the original on 15 October 2018. Retrieved 15 October 2018.
  7. ^ "Dutch program could make Grand Rapids a destination for Parkinson's care". mlive. May 29, 2015. Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  8. ^ "West Michigan scientists find hope in slowing Parkinson's disease". Fox 17 West Michigan News (WXMI). December 22, 2016. Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  9. ^ a b c "Patrik Brundin, MD, PhD | Parkinson's Disease". www.michaeljfox.org. Archived from the original on 2023-08-07. Retrieved 2023-08-07.
  10. ^ a b "UWC - The never-ending Extended Essay: UWC Alumnus on his way to curing Parkinson's Disease". Archived from the original on 2021-11-20. Retrieved 2021-11-20.
  11. ^ a b Marilyn, Sarah (May 4, 2021). "'Close to a breakthrough'". Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  12. ^ "Archived copy". Archived from the original on 2023-08-29. Retrieved 2023-08-29.{{cite web}}: CS1 maint: archived copy as title (link)
  13. ^ a b "Profile: Patrik Brundin | Journal of Parkinson's Disease". Archived from the original on 2021-11-20. Retrieved 2021-11-20.
  14. ^ "Archived copy". Archived from the original on 2023-08-29. Retrieved 2023-08-29.{{cite web}}: CS1 maint: archived copy as title (link)
  15. ^ "Profile: Patrik Brundin". www.journalofparkinsonsdisease.com. Archived from the original on 2021-11-20. Retrieved 2021-11-20.
  16. ^ "The never-ending Extended Essay: UWC Alumnus on his way to curing Parkinson's Disease". Archived from the original on 2021-11-20. Retrieved 2021-11-20.
  17. ^ Thoms, Sue (October 27, 2011). "For Van Andel Institute's new lead scientist in Parkinson's research, fight against disease is personal". mlive. Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  18. ^ "Professor Patrik Brundin co-founder of new biotechnology company". Lund University, Faculty of Medicine. Lund University. Archived from the original on 15 October 2018. Retrieved 15 October 2018.
  19. ^ "Hjärnans mysterier lockade". Kristianstadsbladet. November 6, 2005. Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  20. ^ "Parkinson's brain cell transplants last for years". NBC News. April 6, 2008. Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  21. ^ "Kritisk toppforskare lämnar Lund för USA". Sydsvenskan. November 8, 2011. Archived from the original on 2023-08-07. Retrieved 2023-08-07.
  22. ^ a b c d Watson, Rachel (November 17, 2021). "VAI scientists named to Highly Cited Researchers list". Archived from the original on August 7, 2023. Retrieved August 7, 2023.
  23. ^ Thoms, Sue (June 27, 2012). "Closing in on a Parkinson's drug: Van Andel scientist hopes study will lead to way to halt disease". mlive. Archived from the original on August 11, 2023. Retrieved August 11, 2023.
  24. ^ "Hopp om tidig medicin mot parkinson". Hälsoliv. Archived from the original on 2023-08-11. Retrieved 2023-08-11.
  25. ^ Åkerman, Mikaela (August 14, 2011). "Ny ledtråd om Parkinsons sjukdom". Svenska Dagbladet. Archived from the original on August 11, 2023. Retrieved August 11, 2023 – via www.svd.se.
  26. ^ "The International Linked Clinical Trials (iLCT) programme". Cure Parkinson's. Archived from the original on 2023-08-11. Retrieved 2023-08-11.
  27. ^ "WPCVirtual - World Parkinson Coalition". www.worldpdcoalition.org. Archived from the original on 2023-08-11. Retrieved 2023-08-11.
  28. ^ "eRA Browser Warning". public.era.nih.gov. Archived from the original on 2023-08-11. Retrieved 2024-04-28.
  29. ^ "OPDC Scientific Advisory Board". Oxford Parkinson's Disease Centre. Archived from the original on 15 October 2018. Retrieved 15 October 2018.
  30. ^ a b c d "Academy of Europe: Brundin Patrik". www.ae-info.org. Archived from the original on 2023-03-20. Retrieved 2023-08-07.
  31. ^ "2001 CAG Triplet Repeat Disorders Conference GRC". www.grc.org. Archived from the original on 2023-08-11. Retrieved 2023-08-11.
  32. ^ "Archived copy" (PDF). Archived (PDF) from the original on 2023-08-11. Retrieved 2023-08-11.{{cite web}}: CS1 maint: archived copy as title (link)
  33. ^ Lloyd, Blythe. "Who We Are". Aligning Science Across Parkinson's. Archived from the original on 2023-08-11. Retrieved 2023-08-11.
  34. ^ "WCN 2019 Plenary Sessions". wfneurology.org. Archived from the original on 2023-08-11. Retrieved 2023-08-11.
  35. ^ Murray, Kirsten (September 29, 2022). "2022 Tom Isaacs Award honours leading Parkinson's researchers and co-authors of Ending Parkinson's". Cure Parkinson's. Archived from the original on August 7, 2023. Retrieved August 7, 2023.

Further reading[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Patrik_Brundin&oldid=1221116752"